Infusion Pumps in Colorado

WalkMed Technologies manufactures the WalkMed 350VL, a portable ambulatory infusion pump designed for chemotherapy, antibiotic, and pain management therapies. Founded on principles of safety and reliability, WalkMed specializes exclusively in ambulatory infusion equipment with over 19,000 pumps produced since 2008. The 350VL pump features exceptional battery life (days on a single nine-volt battery), programmable delivery rates (0.1–30 mL/hour with ±5% accuracy), and intuitive user interface requiring no complex sub-menus. The company manufactures all products in the USA under ISO 13485 and FDA Quality System Regulation compliance. WalkMed provides comprehensive customer support 24/7, customization for large fleet deployments, and complementary disposables including reservoir bags, administration sets, and accessories. Used by cancer treatment centers, clinics, and healthcare facilities across the U.S., Europe, and Australia, WalkMed is recognized for durability, ease of use, and long-term cost-effectiveness in ambulatory infusion therapy.

Prescott's is a specialty biomedical equipment and depot solutions provider serving healthcare facilities nationwide. The company operates through multiple specialized divisions—each a leader in its category—offering sales, rentals, maintenance, preventive maintenance, repair, and refurbishing services for surgical and clinical equipment. Core product lines include reconditioned surgical microscopes (since 1984), anesthesia equipment and systems, infusion pumps, patient monitors, sterilizers, washers, and auxiliary surgical equipment. Prescott's emphasizes rapid response (guaranteed 24-hour response time), certified biomedical technicians, component exchange warranties, and service-first partnerships. The company acquired Tenacore to expand depot-based repair, parts distribution, and technical support for patient monitoring, surgical, respiratory, and fluid delivery equipment across multiple modalities.

Terumo BCT, Inc. is a division of Terumo Corporation and a global leader in blood management, blood and cell therapies, and related healthcare solutions. Headquartered in Lakewood, Colorado, Terumo BCT operates as the Blood Management Company within the Terumo Group, serving over 130 countries and regions worldwide. The company develops, manufactures, and distributes medical devices and consumables for blood transfusion management, hemapheresis, cell therapy processing, and related clinical applications. Terumo BCT specializes in automated blood collection, processing, testing, and therapeutic apheresis technologies. The company's product portfolio includes blood management systems, cell and gene therapy manufacturing solutions, and diagnostic equipment for blood banking and transfusion medicine. Terumo BCT maintains regulatory compliance with FDA, ISO 13485, and CE marking requirements. The company operates manufacturing facilities in North America and maintains a robust distribution and service infrastructure supporting hospitals, blood banks, and healthcare institutions globally. As part of the larger Terumo Group, which generated approximately 35% of group sales from North American operations, Terumo BCT represents a significant strategic asset in cellular and blood-based therapeutic innovation and clinical implementation.

XVIVO Perfusion AB is a Sweden-headquartered leader in ex-vivo organ preservation and perfusion technologies for transplantation. The company develops and commercializes machine perfusion systems and consumables designed to extend organ preservation time, increase organ utilization, enable organ assessment, and improve transplant outcomes. Core product lines include Kidney Assist Transport™ (hypothermic pulsatile perfusion device for donor kidneys, up to 24 hours preservation), Liver Assist™ (multi-protocol perfusion platform supporting hypothermic HOPE/DHOPE, normothermic, and sub-normothermic protocols), XPS™ (comprehensive ex-vivo lung perfusion platform for assessment and preservation), and PERFADEX® Plus (standard lung preservation solution used by >90% of transplantation clinics). The company also provides full-service organ recovery services including technology, logistics, staffing, and clinical support. XVIVO serves transplantation centers, organ procurement organizations, and research institutions globally. The company is publicly traded on Nasdaq Stockholm and maintains regulatory compliance through CE marking and FDA submissions (including 510(k) pathway for novel perfusion devices). XVIVO Academy provides clinical training, webinars, and educational resources to support adoption and optimization of organ perfusion protocols.